Incyte plans label expansion for cancer drug Monjuvi following positive topline data
Incyte will go to the FDA by the end of the year with a supplemental BLA for its cancer drug Monjuvi after it hit all …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
